Endothelium-derived and intraneuronal nitric oxide-dependent inhibition of norepinephrine efflux from sympathetic nerves by bradykinin.

Evidence is presented that bradykinin inhibits norepinephrine efflux from sympathetic nerves innervating canine mesenteric and pulmonary arteries, in part, by releasing endothelium-derived relaxing factor (EDRF) from the vascular endothelium. Moreover, in the absence of vascular endothelium, bradykinin also inhibits norepinephrine efflux from the sympathetic nerve terminals innervating these blood vessels. This inhibition is attenuated by canavanine and LNMMA, which inhibit the conversion of arginine to nitric oxide, and is enhanced after overnight incubation of blood vessels with arginine. In endothelium-rubbed blood vessels the inhibitory effect of bradykinin on norepinephrine efflux is enhanced by increasing extracellular calcium ion ([Ca2+]o) and attenuated by nitrendipine. We propose that bradykinin inhibits norepinephrine efflux by stimulating intraneuronal nitric oxide from arginine.

Cyclic GMP modulates release of norepinephrine from adrenergic nerves innervating canine arteries.

Evidence is presented that compounds which stimulate the soluble form of the enzyme guanylate cyclase or which inhibit the enzyme cGMP phosphodiesterase (PDE), responsible for the degradation of cGMP (including endothelium-derived relaxing factor) are inhibitors of sympathetic neurotransmission to vascular smooth muscle and inhibit the efflux of norepinephrine from sympathetic nerves. Moreover, prostacyclin, papaverine, iloprost, and forskolin, compounds which stimulate the enzyme adenylate cyclase, and rolipram (neural specific) and milrinone, enoximone, and piroximone (muscle specific) inhibitors of Type III cAMP PDE and degradation of cAMP, do not inhibit nerve stimulation to most blood vessels. The data support the concept that cGMP may act as a negative feedback modulator of physiologic frequencies of sympathetic nerve activity to blood vessels. cAMP does not appear to modulate adrenergic neurotransmission to vascular smooth muscle at physiologic frequencies of neural stimulation.

Inhibition of sympathetic neurotransmitter release by modulators of cyclic GMP in canine vascular smooth muscle.

The contractile response to neurally released norepinephrine (NE) from sympathetic nerve endings innervating vascular smooth muscle are inhibited by substances which raise either cyclic AMP and cyclic GMP concentrations in smooth muscle. However, cyclic AMP is believed to facilitate NE release from sympathetic nerves whereas the role of cyclic GMP in this process is undefined. We examined the effects of presumed modulation of the intraneuronal concentration of cyclic AMP and cyclic GMP on sympathetic neurotransmission to isolated canine mesenteric artery by measurement of the efflux of [2-14C]NE during transmural nerve stimulation (calcium dependent release of NE) and administration of tyramine (calcium independent release of NE) and measurement of the contractions to exogenous NE and tyramine. Stimulation of adenylate cyclase with forskolin, prostacyclin and iloprost, a stable prostacyclin analog, and inhibition of Type III cyclic AMP phosphodiesterase with neural specific rolipram, 'non-specific pelrinone and milrinone and isobutylmethylxanthine did not enhance the efflux of [2-14C]NE from sympathetic nerves innervating the blood vessels. Isoproterenol enhanced the efflux of [2-14C]NE. The effect was inhibited by propranolol but not affected by milrinone, amrinone or rolipram. Activators of guanylate cyclase (SIN-1a an active metabolic of molsidomine, nitroglycerin and sodium nitroprusside) and inhibitors of Type II cyclic GMP phosphodiesterase (M&B-22948 and verofyllin) inhibited the efflux of NE released by transmural nerve stimulation but not by tyramine. These data support the conclusion that cyclic GMP may be an inhibitory modulator of calcium and depolarization dependent NE release from sympathetic nerves, whereas neuronal cyclic AMP may not be a primary modulator of neurotransmission to vascular smooth muscle.

Release of norepinephrine from adrenergic nerve endings of blood vessels is modulated by endothelium-derived relaxing factor.

The release of norepinephrine from adrenergic nerve endings is inhibited by substances which raise cyclic 3',5'-guanosine monophosphate (cGMP) in neural tissue. Endothelium-derived relaxing factor (EDRF) elevates cGMP in vascular smooth muscle. Thus, EDRF may also modulate the release of norepinephrine (NE) from adrenergic nerves. We tested this postulate in isolated canine pulmonary arteries and veins using the technique of superfusion and measurement of the efflux of radiolabeled NE during transmural nerve stimulation at 1, 2, 4, 8, 16 and 32 Hz for 10 min. In segments of artery and vein with intact endothelium the contractile responses to low frequency nerve stimulation were decreased when compared to endothelium rubbed blood vessels. Electrical stimulation of arteries and veins with intact endothelium for 10 min released less 2-[14C]-NE than rubbed blood vessels, especially at the lower frequencies of 1, 2 and 4 Hz, with lesser effects at frequencies of 16 and 32 Hz. Using the technique of bioassay, EDRF from porcine thoracic aorta inhibited the efflux of 2-[14C]-NE from the pulmonary artery and vein. The findings support the conclusion that the endothelium can inhibit release of NE from sympathetic nerve innervating canine pulmonary artery and vein. The endothelium, in part through EDRF, can act as an endogenous inhibitor or sympathetic neurotransmitter release.

The endothelium modulates adrenergic neurotransmission to canine pulmonary arteries and veins.

We tested the postulate that endothelium-derived relaxing factor (EDRF) modulates adrenergic neuroeffector transmission in isolated canine pulmonary arteries and veins, using the technique of superfusion and measurement of the efflux of [2-14C]NE during transmural nerve stimulation at 1, 2, 4, 8, 16 and 32 Hz for 10 and 30 min. In endothelium-rubbed artery and vein the contractile responses to low frequency nerve stimulation were enhanced, when compared to those from endothelium rubbed blood vessels. Transmural nerve stimulation of endothelium competent arteries and veins for 10 min released less [2-14C]NE than denuded arteries and veins, especially at 1, 2 and 4 Hz, with smaller differences evident at higher frequencies (16 and 32 Hz) of stimulation. Superfusion of endothelium rubbed blood vessels with effluent from canine thoracic aorta decreased the release of [2-14C]NE during nerve stimulation. These findings suggest that the endothelium and EDRF can inhibit release of adrenergic neurotransmitter from canine pulmonary arteries and veins. The endothelium may act as an endogenous modulator of adrenergic neurotransmission to canine vascular smooth muscle.

Numerical solution of power flow in multimode W-type optical fibers.

Transmission characteristics of multimode step-index W-type optical fibers are theoretically investigated by numerically solving the complex power flow equations. Spatial transients of power distribution and power level, as well as transmission length dependence of transmission bandwidth, are calculated for the mode-coupling condition from guided to lossy leaky modes, a characteristic of W-type fibers. The transmission characteristics of W-type fibers change from those of two singly clad reference fibers when the width of the intermediate layer is changed. The trade-off relation between the bandwidth and steady-state loss is also discussed.

Paired optical-fiber switch for optical data-bus systems.

A new type of optical switch, which is suitable for application to data paths with a loop bus-line configuration, is described. The switching action is obtained by moving a fiber directly. The insertion loss in the bypass mode is as low as 0.82 dB. Results of temperature, durability, and vibration tests are also described.

Steady-state characteristics of multimode W-type fibers.

The steady-state characteristics of multimode W-type fibers are investigated by solving the coupled-power equation numerically. It is shown that the steady-state power distributions depend on both the intermediate layer width and the coupling strength. Unlike singly clad fibers, the steady-state loss (coupling-induced loss) in W-type fibers is not proportional to the coupling strength. The loss in W-type fibers varies between the value for two types of singly clad reference fibers as the coupling strength changes.

Microbending losses of doubly clad (W-type) optical fibers.

The microbending of optical fibers causes some additional transmission losses. In this paper, the theoretical and experimental results on the microbending characteristics for doubly clad (W-type) fibers are described. A simple approximation in which W-type fibers are considered as equivalent singly clad fibers is employed to calculate the additional losses due to microbending. It is shown that the additional losses of W-type fibers depend on the optical wavelength. Further, it is shown that the structural imperfections of the guide can be also considered a kind of microbending which affects the spectral loss characteristics of W-type fibers.

W fiber design considerations.

The baseband frequency characteristics and the average confinement of light to core properties of a W fiber are analyzed in conjunction with corresponding singly clad (SC) fibers under some ideal assumptions It is found that the bandwidth of a W fiber is almost equal to that of the SC fiber that has no intermediate layer and is much wider than that of the other SC fiber in which the intermediate layer extends to infinity. The average fractional power flow outside the core in a W fiber is drastically reduced in comparison with both SC fibers. Practical design considerations are deduced from a typical example.